SMOC2

Across TCGA pan-cancer cohorts, SMOC2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SMOC2 data layer compared with 20 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher SMOC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SMOC2 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

DLBC, LAML, and SCLC are the cancer types where SMOC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
LAML	DFS	Median	All	0.028	0.572	<.001	12	view →
SCLC	DFS	Median	II,III,IV	0.137	0.562	.013	12	view →
LUAD	OS	Median	III,IV	0.004	0.662	<.001	9	view →
COAD	DFS	Median	All	0.200	0.691	.006	8	view →
SKCM	DFS	Median	All	0.328	0.764	<.001	8	view →
STAD	DFS	Median	II,III,IV	1.000	0.327	.040	5	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SMOC2–DLBC (OS)

Open the DLBC breakdown →